Clinical trial register · Spain

Clinical Trials in Santander, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Santander

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Not yet open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

2,380

Santander, Santiago de Compostela, Barcelona, Coslada, Girona, Madrid, Málaga, Oviedo

2026-12-16

Not yet open

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188Relapsed or Refractory Multiple Myeloma

DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide

AbbVie

Phase 3

520

Santander, Pamplona, Madrid

2026-11-30

Recruiting

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

NCT07473700Hypertension, Pulmonary, Lung Diseases, Interstitial

Tectonic Operating Company, Inc.

Phase 2

Barcelona, Madrid, Santander

2026-10

Recruiting

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264Secondary Immune Deficiency

DrugHizentra

CSL Behring

Phase 3

Elche, Barcelona, Badalona, Santander, Madrid

2026-09-15

Not yet open

Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma

NCT07763171Gastroesophageal Adenocarcinoma

DrugsRamucirumab·Folfox·Tislelizumab·Paclitaxel

Gruppo Oncologico del Nord-Ovest

Phase 3

244

Barcelona, Madrid, Málaga, Ourense, Pamplona, Santander, Valencia, Zaragoza

2026-09-01

Not yet open

A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

NCT07522801LAL

DrugsEnrylaze·Tofacitinib·Azacitidine·Venetoclax

Philippe ROUSSELOT

Phase 2

Barcelona, Madrid, Málaga, Murcia, Salamanca, San Sebastián, Santander, Seville

2026-09-01

Not yet open

Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

NCT07717099Metastatic Hormone-Sensitive Prostate Cance

DrugsRa223·Darolutamide

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Phase 2

Barcelona, Las Palmas de Gran Canaria, Madrid, Oviedo, Santander, Santiago de Compostela, Valencia, Valladolid

2026-09

Recruiting

The PANHIS Study: Sexual Health in Spanish-Speaking Adults - A Cross-Sectional Online Survey

NCT07746297Sexual Health, Sexual Dysfunction, Physiological, Sexual Dysfunctions, Psychological, Dyspareunia

Menoclinica by Palacios

Observational

15,000

Santander, Madrid

2026-08-30

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Badalona, Barcelona, El Palmar, Madrid, Salamanca, Santander, Seville

2026-08-25

Recruiting

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284High-risk Muscle Invasive Urothelial Carcinoma

DrugsEnfortumab Vedotin·Rilvegostomig·Dato-DXd·Opdivo

AstraZeneca

Phase 3

915

L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Santander, Seville

2026-07-16

Not yet open

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

NCT07578337Untreated, Advanced Pancreatic Cancer

DrugsNLM-001·Botensilimab·Abraxane·Nab-paclitaxel

Nelum Corp

Phase 2

Zaragoza, Barcelona, Santander, San Sebastián, Santiago de Compostela, Málaga

2026-07-15

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Badalona, Barcelona, Madrid, Málaga, Pamplona, Santander, Seville, Valencia

2026-07-10

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

900

Barcelona, Ferrol, Lleida, Madrid, Majadahonda, Málaga, Santander, Seville

2026-07-06

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

A Coruña, Almería, Badalona, Barcelona, León, Madrid, Santander, Santiago de Compostela

2026-06-29

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

NCT07668388Diabetes Mellitus, Type 2

DrugsUBT251·Semaglutide

Novo Nordisk A/S

Phase 2

300

Vic, Barcelona, Centelles (Barcelona), Madrid, Santander, Seville

2026-06-22

Recruiting

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

NCT07596849Graves Disease

DrugEfgartigimod PH20

argenx

Phase 3

230

Santander

2026-06-10

Recruiting

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

NCT07333066Metastatic Hormone-sensitive Prostate Cancer

DrugsApalutamide (Erleada)·Docetaxel

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Phase 3

320

Zaragoza, Barcelona, L'Hospitalet de Llobregat, Santander, Granada, Santiago de Compostela, Madrid, Murcia

2026-06-05

Recruiting

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

NCT07018947Resectable Hepatocellular Carcinoma

DrugAtezolizumab and Bevacizumab

Fundacion Clinic per a la Recerca Biomédica

Phase 2

Badalona, Barcelona, Santander, Córdoba, Girona, Madrid, Puerto de la Torre, Valencia

2026-06-02

Not yet open

Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

NCT07593040Renal Cell Carcinoma

DrugsLenvatinb·Belzutifan

Vall d'Hebron Institute of Oncology

Phase 2

150

Córdoba, Zaragoza, Santander, Barcelona, L'Hospitalet de Llobregat, Sabadell, Lugo, Ourense

2026-06

Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

700

Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Salamanca, Santander

2026-05-31

Recruiting

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

NCT07387549Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 3

350

Barcelona, Córdoba, Madrid, Pontevedra, Santander, Valencia, Zaragoza

2026-05-14

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Santiago Compostela, Seville, Badalona, L'Hospitalet de Llobregat, Santander, Cáceres, Reus, A Coruña

2026-05-11

Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031Solid Tumors

DrugsAdagrasib·Fluorouracil·Leucovorin·Irinotecan

Mirati Therapeutics Inc.

Phase 2

170

A Coruña, Palma, Barcelona, Badalona, Santander, Madrid, Pamplona, Valencia

2026-05-06

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)

Liquidia Technologies, Inc.

Phase 3

344

Barcelona, Santander

2026-04-23

Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07419295Bladder Cancer

DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

590

Badalona, Santander, Las Palmas de Gran Canaria, Madrid, Barcelona, Seville

2026-04-23

Recruiting

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332Pulmonary Arterial Hypertension

Inhibikase Therapeutics

Phase 3

486

Málaga, Barcelona, Santander, Madrid, Marbella, Seville, Toledo, Valencia

2026-04-23

Recruiting

Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)

NCT07611747Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondy, Systemic Lupus Erythematosus (SLE)

Instituto de Investigación Marqués de Valdecilla

Phase 4

1,944

Alicante, Elche, Orihuela, Barcelona, Laredo, Santander, Torrelavega, Ciudad Real

2026-04-22

Recruiting

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07509307Obesity, Overweight, Osteoarthritis, Knee

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-20

Recruiting

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

245

Barcelona, Córdoba, Galdakao, Madrid, Sabadell, Santander, Seville, Valencia

2026-04-13

Recruiting

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07481630Obesity, Knee Osteoarthritis (OA)

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-13

Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073Solid Tumors

DrugINCB161734

Incyte Corporation

Phase 3

588

Badalona, Barcelona, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Santander, Seville, Valencia

2026-04-09

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Santander, A Coruña, Pamplona, Barcelona, Madrid, Seville, Valencia

2026-03-16

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

DrugsPumitamig·Folfox·Nivolumab

Bristol-Myers Squibb

Phase 2/3

690

Barcelona, Santander, Pamplona, Valencia, Madrid, Málaga

2026-03-13

Recruiting

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

NCT07421700Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma

DrugsPF-08634404·Enfortumab Vedotin

Pfizer

Phase 1/2

132

Barcelona, Santander, Madrid, Seville

2026-03-11

Recruiting

Study on Prostate Salvage Using High-dose-rate Brachytherapy

NCT07860528Prostate Cancer, Locally Recurrent Cancer, Biochemically Recurrent Prostate Carcinoma, Toxicity Radiation

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Observational

Benidorm, L'Hospitalet de Llobregat, Santander, Córdoba, San Sebastián, Madrid, Pamplona, Vigo

2026-03-11

Recruiting

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

NCT07286058Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,182

Santander

2026-03-11

Recruiting

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

NCT07194382Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

160

Badalona, Granollers, Santander, Barcelona, Madrid, Málaga

2026-03-10

Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

DrugsIdelalisib·Pirtobrutinib

Eli Lilly and Company

Phase 4

150

Santander, Seville

2026-03-09

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Barcelona, Huelva, Madrid, Pamplona, Santander, Santiago de Compostela, Seville, Valladolid

2026-03-05

Recruiting

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

NCT07015892Small Cell Lung Carcinoma

Instituto de Investigación Biomédica de Salamanca

Phase 3

300

Salamanca, Almería, Barakaldo, Girona, Las Palmas de Gran Canaria, Madrid, Murcia, Santander

2026-03-01

Recruiting

LONG NAGOMI™ PMCF STUDY

NCT07399002Coronary Artery Disease, Ischemic Heart Disease

Fundación EPIC

Observational

1,039

Cabueñes, Ciudad Real, Elche, Huelva, León, Málaga, Pamplona, Santander

2026-02-27

Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657Relapsed Refractory Multiple Myeloma

DrugsAZD0120·Darzalex·Velcade·Carfilzomib

AstraZeneca

Phase 3

508

Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia

2026-02-23

Recruiting

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

NCT07624838CD30-Positive Peripheral T-Cell Lymphoma

DrugBrentuximab Vedotin

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Observational

100

A Coruña, Palma de Mallorca, Badalona, Barcelona, L'Hospitalet de Llobregat, Sant Joan Despí, Santander, Jerez de la Frontera

2026-02-15

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

A Coruña, Almería, Barcelona, Ferrol, Palma de Mallorca, Pozuelo de Alarcón, Santander, Seville

2026-02-10

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Santander, Seville, Valencia

2026-02-05

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Barcelona, Madrid, Pamplona, Santander, Santiago de Compostela, Valencia

2026-02-03

Recruiting

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654Eosinophilic Asthma

DrugKT-621

Kymera Therapeutics, Inc.

Phase 2

264

Cadiz, Jerez de la Frontera, Madrid, Mataró, Santander

2026-01-28

Recruiting

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452Multiple Myeloma

DrugsEtentamig·Daratumumab·Lenalidomide·Dexamethasone

AbbVie

Phase 2/3

680

Santiago de Compostela, Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, León, Madrid

2026-01-08

Recruiting

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

NCT07138196Chronic Graft-Versus-Host Disease

DrugAdrixetinib

Qurient Co., Ltd.

Phase 1

Barcelona, Madrid, Majadahonda, Murcia, Pamplona, Santander, Seville, Valencia

2025-12-23

Recruiting

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

NCT06932562Multiple Myeloma

DrugsLinvoseltamab·Daratumumab·Lenalidomide·Dexamethasone

European Myeloma Network B.V.

Phase 3

1,000

Badalona, Barcelona, Madrid, Santander, Valencia

2025-12-23

Recruiting

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

NCT07234695Down Syndrome, Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Dementia

DrugLevetiracetam

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 3

120

Granada, Donostia / San Sebastian, Santander, Barcelona, Madrid

2025-12-22

Recruiting

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818Graves Disease

Merida Biosciences

Phase 1

100

A Coruña, Barcelona, Santander, Seville

2025-12-19

Recruiting

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

NCT07301034Myocardial Infarction

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

332

Madrid, Santander

2025-12-18

Recruiting

Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease

NCT07368933Angina (Stable), CAD - Coronary Artery Disease, Unstable Angina, NSTEMI - Non-ST Segment Elevation MI

Advanced NanoTherapies

Not applicable

Barcelona, Santander, Vigo

2025-12-15

Recruiting

Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry

NCT07256249Cardiovascular Diseases

Fundación EPIC

Observational

960

Vilagarcía de Arousa, Badalona, Barcelona, León, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Seville

2025-12-11

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Barcelona, L'Hospitalet de Llobregat, Madrid, Santander

2025-12-04

Recruiting

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Alexion Pharmaceuticals, Inc.

Phase 2

Barcelona, Pamplona, San Sebastián de los Reyes, Santander, Seville

2025-11-26

Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan·Cabozantinib

Merck Sharp & Dohme LLC

Phase 3

904

L'Hospitalet de Llobregat, Santander, Girona, Madrid, Valencia, Barcelona, Córdoba

2025-11-26

Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

NCT07211958Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 3

468

Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Santander, Oviedo, Alicante, Barcelona, Burgos

2025-11-25

Recruiting

Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice

NCT07252765Type 2 Diabetes Mellitus (T2DM), Malnutrition, Malnourishment, Drug-Induced Diabetes

Outcomes'10

Observational

334

Santander, Huelva, Las Palmas de Gran Canaria, Madrid, Málaga, Oviedo, Seville, Valencia

2025-11-20

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

600

A Coruña, Barcelona, Córdoba, Granada, Madrid, Málaga, Palma de Mallorca, Santander

2025-11-18

Recruiting

A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa

NCT07284342Advanced Parkinson's Disease

AbbVie

Observational

103

Málaga, Palma, Badalona, Santander, Cartagena, Gijón, Seville, Almería

2025-11-17

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

NCT07059845Ovarian Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab·Carboplatin

AbbVie

Phase 2

400

Santander, Donostia / San Sebastian, Las Palmas de Gran Canaria, Majadahonda, Seville, A Coruña, Barcelona, Girona

2025-11-13

Active, closed

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,060

Santander, Barcelona, Madrid, Seville, Valencia

2025-11-12

Recruiting

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)

AstraZeneca

Phase 1/2

Badalona(Barcelona), Barcelona, Salamanca, Santander, Valencia

2025-11-12

Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 3

600

Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, Madrid, Málaga, Seville

2025-10-24

Recruiting

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

NCT07465848Lung Cancer (Diagnosis), Health Adult Subjects, Patient

Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)

Not applicable

1,200

Elche, Barcelona, Santander, Madrid, Oviedo, Toledo, Valencia

2025-10-08

Active, closed

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390Arthritis, Rheumatoid

DrugsTulisokibart·Methotrexate

Merck Sharp & Dohme LLC

Phase 2

185

Sabadell, Santander, Santiago de Compostela, Barcelona

2025-10-08

Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488Multiple Myeloma

DrugsMezigdomide·Elranatamab·Dexamethasone

Celgene

Phase 1/2

Santander, Salamanca

2025-10-07

Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857Multiple Myeloma

DrugsCilta-cel·Fludarabine·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Seville

2025-10-03

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Valencia

2025-10-01

Not yet open

Randomized a Clinical Trial With Medical Device in Acute Ischemic Stroke

NCT07113184Acute Ischemic Stroke

Instituto de Investigación Marqués de Valdecilla

Not applicable

220

Burgos, Salamanca, Santander

2025-10-01

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Barcelona, Santander, Madrid, Valencia, Badajoz, Córdoba, Seville

2025-09-30

Recruiting

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

NCT07053423Chronic Obstructive Pulmonary Disease

DrugDupilumab

Sanofi

Phase 4

218

Santander, Barcelona, Pozuelo de Alarcón, Oviedo, Madrid

2025-09-22

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Zaragoza, Badalona, Santander, Barcelona, Madrid

2025-09-17

Active, closed

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

NCT06992609Small Cell Lung Carcinoma

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Badajoz, Barakaldo, Barcelona, Madrid, Málaga, Oviedo, Santander

2025-09-15

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

A Coruña, Barcelona, Málaga, Santander, Santiago de Compostela, Seville, Valladolid

2025-09-15

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Santander, Seville

2025-09-08

By invitation

Impact of Inspiratory Muscle Training (IMT) With Intermittent Variable Resistance (IVR) Versus Constant Resistance (CR) on Functional Capacity in Lung Transplantation (LTx) Patients (I-TRAIN-LTx Study)

NCT06963190Lung Transplantation

Hospital Universitario Marqués de Valdecilla

Not applicable

Santander

2025-08-31

Recruiting

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908Chronic Hepatitis D Infection

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 3

172

Almería, Barcelona, Madrid, Málaga, Santander, Vigo

2025-08-27

Active, closed

A Study of SPY072 in Rheumatic Disease

NCT07148414Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases

DrugSPY072

Spyre Therapeutics, Inc.

Phase 2

285

A Coruña, Chiclana de la Frontera, Santander, Seville

2025-08-21

Active, closed

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872Type 2 Diabetes Mellitus

DrugsRO7795081·Semaglutide

Hoffmann-La Roche

Phase 2

330

Seville, Santander, Castilleja de la Cuesta, A Coruña, Ferrol, Malaga, Málaga, Barcelona

2025-08-19

Recruiting

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

NCT07099898Neoplasms, Lung

DrugsRis-Rez·Risvutatug rezetecan·Topotecan

GlaxoSmithKline

Phase 3

420

Barcelona, L'Hospitalet de Llobrega, Las Palmas de Gran Canar, Madrid, Santander

2025-08-11

Recruiting

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

NCT06892054Pancreatic Adenocarcinoma

DrugSotorasib

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Phase 1

Zaragoza, Barcelona, Santander, Córdoba, Donostia / San Sebastian, Madrid, Málaga, Pamplona

2025-08-08

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338Non-Small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

278

A Coruña, Madrid, Manresa, Málaga, Santander, Valencia

2025-08-07

Active, closed

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

NCT07092865Respiratory Syncytial Virus Infections

GlaxoSmithKline

Phase 2

168

A Coruña, Barcelona, Córdoba, Madrid, Santander

2025-08-06

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Barcelona, Girona, Madrid, Majadahonda, Málaga, Oviedo, Sabadell, Santander

2025-08-06

Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsPemetrexed /m^2·Carboplatin (AUC 5)·Visugromab·Visugromab RDE

CatalYm GmbH

Phase 2

107

Jaén, Málaga, Seville, Santander, Barcelona, Pamplona, Santiago de Compostela, Rioja

2025-08-01

Active, closed

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

NCT07128550Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 3

150

Barcelona, Madrid, Santander

2025-07-30

Recruiting

A Study With CIT-013 in RA Patients

NCT06567470Rheumatoid Arthritis

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

A Coruña, Barcelona, Madrid, Santander, Santiago de Compostela

2025-07-29

Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502Follicular Lymphoma

DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine

Celgene

Phase 3

400

Sabadell, Santander, Madrid, Valencia, Granada

2025-07-28

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Castilleja de la Cuesta, Córdoba, Jaén, Málaga, Seville, San Cristóbal de La Laguna, Santander, Badalona

2025-07-25

Recruiting

Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)

NCT07113223Heart Failure, Cardiovascular Risk Factors

Idoven 1903 S.L.

Not applicable

1,968

Madrid, Santander

2025-07-23

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Badalona, Santander, A Coruña, Barcelona, Madrid, Seville

2025-07-21

Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

DrugsZanzalintinib·Everolimus

Exelixis

Phase 2/3

440

Barcelona, Madrid, Murcia, Oviedo, Santander, Santiago de Compostela, Seville, Valencia

2025-07-21

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Barcelona, Donostia / San Sebastian, Santander, Pozuelo de Alarcón, Valencia, Madrid

2025-07-21

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712Gastroesophageal Adenocarcinoma

DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan

AstraZeneca

Phase 2

100

Barcelona, Elche, Madrid, Málaga, Ourense, Oviedo, Santander, Valencia

2025-07-17

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux

Merck Sharp & Dohme LLC

Phase 3

477

Badalona, Santander, Las Palmas de Gran Canaria, Oviedo, Barcelona, Madrid, Seville, Valencia

2025-07-16

Recruiting

Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis

NCT06533852Decompensated Cirrhosis

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Phase 3

190

Barcelona, Madrid, Sabadell, Santander

2025-07-16

Recruiting

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis

DrugsUplizna·Inebilizumab·Blinatumomab

Amgen

Phase 2

220

Santander, Barcelona, Madrid

2025-07-16

Active, closed

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06991556Metastatic Hormone-sensitive Prostate Cancer

DrugsLuxdegalutamide·Abiraterone·Enzalutamide

Novartis Pharmaceuticals

Phase 2

168

Santander, Badajoz, Lugo, Barcelona, Córdoba

2025-07-07

Recruiting

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

NCT07045909De Novo Multiple Myeloma, Anitocabtagene Autoleucel

DrugsAnitocabtagene Autoleucel·Isatuximab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville

2025-06-30

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Benalmádena, Granollers, Madrid, Málaga, Mérida, Pozuelo de Alarcón, Santander

2025-06-27

Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration

DrugTYRA-300

Tyra Biosciences, Inc

Phase 2

Barcelona, Madrid, Santander

2025-06-27

Active, closed

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

NCT06736990Idiopathic Pulmonary Fibrosis

Calluna Pharma AS

Phase 2

150

Barcelona, Santander, Santiago de Compostela

2025-06-20

Recruiting

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

NCT06856213Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

DrugsCetuximab·Paclitaxel

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 2

Santiago de Compostela, Badalona, Barcelona, Santander, Granada, A Coruña, Lugo, Madrid

2025-06-18

Active, closed

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

NCT06958315Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia

Novartis Pharmaceuticals

Observational

219

Cadiz, Granada, Huelva, Jaén, Marbella, Mallorca, Puerto Real, Santander

2025-06-16

Recruiting

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034Gastrointestinal Neoplasms

DrugRisvutatug rezetecan

GlaxoSmithKline

Phase 1/2

451

Barcelona, HebrOn, Madrid, Pamplona, Santander, Zaragoza

2025-06-11

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Barcelona, LHospitalet de Llobregat, Madrid, Marbella, Salamanca, Santander, Seville

2025-06-11

Active, closed

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

NCT06906822Melanoma

DrugsEnfortumab Vedotin·Pembrolizumab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Badalona, Barcelona, Santander, Madrid, Murcia, Seville, Valencia

2025-06-10

Active, closed

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C

DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir

Atea Pharmaceuticals, Inc.

Phase 3

880

Santander, Málaga, Vigo, Barcelona

2025-06-02

Not yet open

Clinical Trial to Evaluate Three Systems of Osteosynthesis for Fixation of Olecranon Osteotomies in Adults

NCT07014358Olecranon Fracture

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase 4

105

Santander, Madrid, Valencia

2025-06

Recruiting

Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis

NCT07236970Pulmonary Hypertension, Systemic Sclerosis (SSc), Systemic Sclerosis-Associated PAH

Alejandro Cruz Utrilla

Observational

350

Granada, Santander, Barcelona, Madrid

2025-05-30

Recruiting

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

NCT06887088Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases

DrugsFianlimab·Binimetinib·Encorafenib·Cemiplimab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Barcelona, Burgos, Santander, Cáceres, Donostia / San Sebastian, Madrid, Majadahonda

2025-05-29

Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301Advanced Melanoma

DrugsEIK1001·Keytruda·Pembrolizumab

Eikon Therapeutics

Phase 2/3

740

Santiago de Compostela, Badalona, Barcelona, Santander, Cáceres, Lugo, Girona, Madrid

2025-05-22

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581Asthma

DrugTilrekimig

Pfizer

Phase 2

252

Santander, Madrid, Pozuelo de Alarcón, Málaga

2025-05-20

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Santander, Santiago de Compostela, Majadahonda Madrid, Madrid, Barcelona, Córdoba, Lugo, Seville

2025-05-13

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Palma, Santander, Barcelona, Madrid, Seville, Toledo

2025-05-12

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Barcelona, Madrid, Santander

2025-05-06

Recruiting

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805Idiopathic Pulmonary Fibrosis

Mediar Therapeutics

Phase 2

164

Barcelona, Lugo, Madrid, Santander

2025-05-05

Active, closed

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413Obesity, Overweight, Overweight With One Weight Related Comorbidity

DrugsRO7204239·Tirzepatide

Hoffmann-La Roche

Phase 2

285

Seville, Santander, Castilleja de la Cuesta, A Coruña, Barcelona, Málaga

2025-05-05

Active, closed

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

905

A Coruña, Barcelona, Ferrol, Móstoles, Santander, Seville

2025-04-25

Recruiting

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463Metastatic Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Panitumumab·Fluorouracil·Leucovorin

AbbVie

Phase 2

390

Santander, Pamplona, Barcelona, Madrid, Valencia

2025-04-24

Active, closed

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142Sjogren Disease

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2

Santander, Castelló, Madrid, Torrevieja

2025-04-23

Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

340

Granada, Barcelona, Santander, Madrid, Málaga

2025-04-17

Active, closed

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

NCT06864169Gastrointestinal Cancer

DrugR-DXd

Merck Sharp & Dohme LLC

Phase 2

160

Badalona, Santander, Barcelona, Madrid

2025-04-01

Recruiting

Comparison Between Bipolar Transurethral Resection of the Prostate and Moses Assisted Holmium Laser Enucleation of the Prostate

NCT06649357Prostate Hyperplasia, Surgery, Endoscopic Anatomical Enucleation of the Prostate (EEAP)

Fundacio Puigvert

Not applicable

130

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Santander, Gijón, Valladolid

2025-04-01

Not yet open

Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia

NCT06830733Leukemia, Plasma Cell

Fundacion Clinic per a la Recerca Biomédica

Phase 2

Santander, Madrid, Murcia, Pamplona, Salamanca, Barcelona

2025-04

Recruiting

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263Asthma

DrugTozorakimab

AstraZeneca

Phase 2

540

Barcelona, Madrid, Málaga, Mérida, Patraix, Santander

2025-03-26

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Santander, Galdacao, Madrid, Murcia, Valencia, Valladolid

2025-03-17

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Córdoba, Barcelona, Sabadell, Barakaldo, Santander, Lugo, Madrid, Majadahonda

2025-03-13

Recruiting

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Barcelona, Madrid, Málaga, Pamplona, Santander, Valencia

2025-03-12

Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466Menstrual Migraine

DrugRimegepant

Pfizer

Phase 3

723

Barcelona, Santander, Chiclana de la Frontera, Madrid, Seville, Valladolid, Zaragoza

2025-03-11

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671496Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

600

Vitoria-Gasteiz, Santander, Alcobendas, Madrid, Santa Cruz de Tenerife, Seville

2025-03-10

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Santander, Seville, A Coruña, Alicante, Barcelona, Málaga

2025-03-06

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Badalona, Barcelona, Madrid, Ourense, Santander, Seville, Valencia

2025-03-01

Recruiting

Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM)

NCT06908785Cirrhosis, Liver

Instituto de Investigación Marqués de Valdecilla

Observational

330

Santander, Alicante, Barcelona, Bilbao, Burgos, Madrid, Oviedo, Toledo

2025-03-01

Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

780

Barakaldo, Santander, Badajoz, Las Palmas, Madrid, Sevilla, Marbella, Seville

2025-02-27

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

A Coruña, Barcelona, Córdoba, Madrid, Málaga, Sabadell, Santander, Seville

2025-02-21

Active, closed

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053Asthma

DrugGSK5784283

GlaxoSmithKline

Phase 2

307

Alcorcon Madrid, Barcelona, Benalmádena, Jerez de la Frontera, Madrid, Málaga, Santander, Seville

2025-02-10

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

216

Barcelona, Santander, L'Hospitalet de Llobregat, Pamplona, Madrid

2025-02-06

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Badalona, Barcelona, Madrid, Pamplona, Santander, Valencia

2025-01-28

Active, closed

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

NCT06133517Urothelial Bladder Carcinoma

DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan

Fundación para el Progreso de la Oncología en Cantabria

Phase 2

L'Hospitalet de Llobregat, Santander, Madrid, Pamplona, Toledo, Valladolid

2025-01-20

Recruiting

Evaluation of the Family Intervention Program (PIF)

NCT07106775Parenting, Children/Adolescent Adjustment, Family Functioning

University of Seville

Not applicable

Santander

2025-01-15

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

A Coruña, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Santander, Santiago de Compostela, Seville

2025-01-09

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugPirtobrutinib

Loxo Oncology, Inc.

Phase 2

249

Barcelona, L'Hospitalet Del Llobregat, Madrid, Majadahonda, Marbella, Oviedo, Salamanca, Santander

2025-01-03

Recruiting

Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).

NCT07814924Chronic Rhinosinusitis With Nasal Polyps

DrugMepolizumab

Instituto de Investigación Marqués de Valdecilla

Phase 4

Barakaldo, Jerez de la Frontera, Madrid, Salamanca, Santander, Seville, Valladolid

2024-12-31

Not yet open

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

NCT05982275Multiple Myeloma, Allogeneic Stem Cell Transplantation

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 1/2

Santander, Barcelona, Salamanca, Seville, Valencia

2024-12-30

Recruiting

Early Transcatheter Mitral Valve Repair After Myocardial Infarction

NCT06282042Acute Mitral Regurgitation

Fundación para la Investigación Biosanitaria del Principado de Asturias

Not applicable

250

Alicante, Barcelona, L'Hospitalet de Llobregat, Santander, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga

2024-12-24

Active, closed

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256Idiopathic Inflammatory Myopathies

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-12-17

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander

2024-12-16

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Barcelona, Huelva, Madrid, Pamplona, Santander, Seville

2024-12-04

Recruiting

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

NCT07254754DIFFUSE LARGE B-CELL LYMPHOMA

DrugAxicabtagene Ciloleucel

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

A Coruña, Palma de Mallorca, Santander, Salamanca, Barcelona, L'Hospitalet de Llobregat, San Sebastián, Las Palmas de Gran Canaria

2024-11-20

Active, closed

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329Non-Small Cell Lung Cancer

DrugsMarlotamig·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

120

Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Madrid, Seville, Valencia, Zaragoza

2024-11-18

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

Barcelona, León, Madrid, Salamanca, Santander, Valencia

2024-11-11

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Santiago de Compostela, Badalona, Santander, Barcelona, Madrid, Benalmádena, Girona, Málaga

2024-11-07

Active, closed

A Study of Mosliciguat in PH-ILD

NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases

DrugMosliciguat

Pulmovant, Inc.

Phase 2

135

Santander, Marbella, Madrid, Toledo

2024-10-29

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-10-29

Active, closed

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193Parkinson Disease

Denali Therapeutics Inc.

Phase 2

Barcelona, Donostia / San Sebastian, Madrid, Santander, Seville

2024-10-24

Recruiting

The Sagittarius Trial

NCT06490536Colon Cancer Stage II, Colon Cancer Stage III

DrugsFolinic acid·Panitumumab·Pertuzumab·Temozolomide

IFOM ETS - The AIRC Institute of Molecular Oncology

Phase 3

700

Barcelona, Valencia, Córdoba, Madrid, Pamplona, Santander, Santiago de Compostela, Zaragoza

2024-10-22

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, Santiago de Compostela

2024-10-14

Active, closed

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168Primary Biliary Cholangitis

Ipsen

Observational

424

Almería, Barcelona, Madrid, Pontevedra, Santander

2024-10-14

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Barcelona, El Palmar, Granada, Granvia de L'hospitalet 199-203, Madrid, Málaga, Salamanca, Santander

2024-10-11

Active, closed

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060Episodic Migraine, Chronic Migraine

DrugCorabotase

Ipsen

Phase 2

670

Barcelona, Cadiz, Madrid, Santander, Seville, Valladolid

2024-10-10

Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

DrugsNadofaragene Firadenovec·Docetaxel·Gemcitabine·Pembrolizumab

Ferring Pharmaceuticals

Phase 3

250

Santander, Barcelona, Córdoba, A Coruña, Alcorcón, Madrid, Pamplona, Bilbao

2024-10-01

Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer

DrugNadofaragene Firadenovec

Ferring Pharmaceuticals

Phase 3

454

Santander, Barcelona, Córdoba, A Coruña, Granada, Alcorcón, Madrid, Bilbao

2024-10-01

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Barcelona, León, Madrid, Santander, Seville, Valencia, Valladolid, Vigo

2024-09-27

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

400

Santander, Valencia

2024-09-17

Recruiting

European Registry of Next Generation Imaging in Advanced Prostate Cancer

NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)

Fundacio Puigvert

Observational

600

Barcelona, Córdoba, Madrid, San Cristóbal de La Laguna, Santander, Santiago de Compostela

2024-09-17

Recruiting

Sacituzumab govitEcan in THYroid Cancers

NCT06235216Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer

DrugSacituzumab Govitecan

Grupo Espanol de Tumores Neuroendocrinos

Phase 2

Barcelona, Ferrol, Hospitalet de Llobregat (Barcelona), Madrid, Murcia, Oviedo, Santander, Zaragoza

2024-09-13

Recruiting

Trajectories of Anxiety and Depression in Cancer Patients, Risk and Predictive Factors and Supportive Care; Prognostic Awareness and Shared Decision Making.

NCT07168096Depression, Cancer, Anxiety

Fundación Sociedad Española de Oncologia Médica

Observational

540

Santander, Ciudad Real, Cuenca, Alicante, Arganda, Fuencarral-El Pardo, Fuenlabrada, Salamanca

2024-09-12

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Pamplona Iruna, Barcelona, Córdoba, Granada, Madrid, Málaga, Santander, Seville

2024-09-11

Active, closed

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

179

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Salamanca, Valencia

2024-09-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Sabadell, Santander, Majadahonda, Barcelona, Madrid, Seville, Valencia

2024-09-04

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

Gossamer Bio USA, Inc.

Phase 3

330

Barcelona, Madrid, Santander, Seville, Toledo

2024-09-03

Recruiting

CRS Questionnaire Validation Project

NCT06970977Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

The European Forum for Research and Education in Allergy and Airway Diseases

Observational

1,000

A Coruña, Barcelona, Cadiz, Madrid, Ponferrada, Santander, Seville, Valencia

2024-09-01

Active, closed

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

DrugsS095029·Keytruda·Pembrolizumab

Servier Bio-Innovation LLC

Phase 1/2

Barcelona, Madrid, Santander, Valencia

2024-08-31

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

A Coruña, Alcorcón, Barcelona, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela

2024-08-27

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Badalona, Barcelona, El Palmar, Madrid, Pamplona, Salamanca, Santander, Seville

2024-08-23

Active, closed

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025Multiple Myeloma

DrugsCilta-cel·Talquetamab·Teclistamab·Bortezomib

Janssen Research & Development, LLC

Phase 2

Madrid, Salamanca, Santander

2024-08-20

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Barcelona, Madrid, Málaga, Santander

2024-08-12

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Barcelona, El Palmar, Girona, Las Palmas de Gran Canaria, Madrid, Oviedo, Pamplona, Santander

2024-08-07

Recruiting

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

NCT06979323Asthma

DrugDepemokimab

GlaxoSmithKline

Phase 3

150

Barcelona, Benalmádena, Madrid, Palma de Mallorca, Santander

2024-07-19

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsLumakras·Sotorasib·Bevacizumab-awwb·Panitumumab

Amgen

Phase 3

450

Córdoba, Granada, Málaga, Seville, Zaragoza, Santander, Burgos, Badalona

2024-07-17

Recruiting

TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias

NCT07798674Hereditary Spastic Paraplegia, Spastic Ataxia

Heidelberg University

Observational

4,000

Barcelona, Santander

2024-07-16

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Badalona, L'Hospitalet de Llobregat, Santander, Barcelona, Madrid, Marbella, Salamanca

2024-07-16

Recruiting

Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer

NCT06582628Metastatic Prostate Cancer

DrugEnzalutamide

Fundacion Oncosur

Phase 2

Badalona, Barcelona, Sabadell, Santander, Cadiz, Madrid, Málaga, Barakaldo

2024-07-05

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Sabadell, Santander, Manises, Madrid, Málaga, Valencia

2024-06-27

Active, closed

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424Alpha 1-Antitrypsin Deficiency, Emphysema

Sanofi

Phase 2

185

Santander, Madrid, Santiago de Compostela

2024-06-20

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2024-06-07

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297Neutropenia

X4 Pharmaceuticals

Phase 3

176

Barcelona, Cáceres, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville, Valencia

2024-06-06

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Santander, El Palmar, A Coruña, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid

2024-06-05

Active, closed

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma

DrugsVenclyxto·Ibrutinib·Venclexta·Venetoclax

Janssen Research & Development, LLC

Phase 2

333

Barcelona, Córdoba, Madrid, Santander, Santiago de Compostela

2024-05-30

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

89bio, Inc.

Phase 3

762

Almería, Badalona, Barcelona, Córdoba, Madrid, Málaga, Pontevedra, Santander

2024-05-24

Recruiting

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

NCT06133972Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

550

Santiago Compostela, Badalona, Santander, Barcelona, San Sebastian Reyes, Madrid, Valencia

2024-05-21

Active, closed

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 1

Santander, Barcelona, Cáceres, Granada, Madrid, Salamanca, Seville, Valencia

2024-05-21

Recruiting

CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

NCT06926205Richter Syndrome

DrugMosunetuzumab

GELLC (Grupo Español de Leucemia Linfocítica Crónica)

Phase 2

Barcelona, L'Hospitalet de Llobregat, Santander, Las Palmas de Gran Canaria, Madrid, Murcia, Marbella, Oviedo

2024-05-15

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

450

Santander, A Coruña, Pamplona, Oviedo, Barcelona, Madrid

2024-05-03

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

Badalona, Barcelona, Madrid, Málaga, Sabadell, Santander, Seville, Valencia

2024-04-09

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

375

Granada, Barcelona, Santander, Madrid, Málaga, Oviedo, Seville, Cadiz

2024-04-03

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

89bio, Inc.

Phase 3

1,350

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pontevedra, Santander, Santiago de Compostela

2024-03-13

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Barcelona, Madrid, Ourense, Santander, Seville

2024-03-04

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Badalona, L'Hospitalet de Llobregat, Santander, Pamplona, Barcelona, Cáceres, Madrid, Salamanca

2024-02-05

Active, closed

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

NCT05955508Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

Santiago de Compostela, Granada, Palma Mallorca, Badalona, Santander, Pozuelo de Alarcón, El Palmar, Pamplona

2024-01-30

Active, closed

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596Metastatic Urothelial Cancer

DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin

BicycleTx Limited

Phase 2

375

Barcelona, Las Palmas de Gran Canaria, Madrid, Pamplona, San Sebastián, Santander, Santiago de Compostela, Valencia

2024-01-24

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Santander, Barcelona, Madrid, Málaga, Salamanca, Seville, Valencia

2024-01-23

Active, closed

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT06109272Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Tremelimumab·Atezolizumab

AbbVie

Phase 2/3

Santander, Majadahonda, Barcelona, Córdoba, Madrid, Seville, Zaragoza

2024-01-11

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Alicante, Badalona, Barcelona, Cadiz, Madrid, Málaga, Santander, Valencia

2024-01-11

Active, closed

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079281Hypophosphatasia

DrugALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

124

Barcelona, Granada, Madrid, San Cristóbal de La Laguna, Santander, Vitoria-Gasteiz

2024-01-03

Recruiting

Effectiveness of an ACT-Based Cognitive Intervention on Quality of Life and Cognitive Function in Elderly Residents With MCI

NCT06753578Mild Cognitive Impairment

Instituto de Investigación Marqués de Valdecilla

Not applicable

215

Santander

2024-01-01

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

DrugsOdronextamab·Lenalidomide·Rituximab

Regeneron Pharmaceuticals

Phase 3

580

Santiago de Compostela, Palma, L'Hospitalet de Llobregat, Santander, Pozuelo de Alarcón, Oviedo, Barcelona, Granada

2023-12-28

Recruiting

Observational Study Protocol: LIVER-R

NCT06252753Hepatobiliary Cancers

AstraZeneca

Observational

4,000

Santiago de Compostela, Zaragoza, Poniente Sur, Santander, Burgos, Ourense, Majadahonda, El Palmar

2023-12-20

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 3

400

Barcelona, Palma de Mallorca, Santander, Valencia

2023-12-20

Recruiting

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation

NCT05955365Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation, P2Y12 Inhibitor

DrugsDOAC·Aspirin

Insel Gruppe AG, University Hospital Bern

Phase 4

3,010

Santander

2023-12-18

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

904

Santiago de Compostela, Seville, Palma, Badalona, Sabadell, Terrassa, Santander, A Coruña

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Santiago de Compostela, Málaga, Seville, Palma, Barakaldo, Santander, A Coruña, Pozuelo de Alarcón

2023-12-12

Active, closed

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256Idiopathic Pulmonary Fibrosis

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

145

L'Hospitalet de Llobregat, Sabadell, Santander, Majadahonda, Oviedo, Barcelona, Cadiz, Girona

2023-12-11

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander

2023-12-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Sabadell, Santander, Majadahonda, Valencia, Barcelona, Madrid, Seville

2023-12-01

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Barcelona, Granada, Hospitalet deLlobregat, Madrid, Pamplona, Santander

2023-11-23

Active, closed

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

NCT06282978Multiple Myeloma in Relapse

DrugElranatamab

PETHEMA Foundation

Phase 2

Santiago de Compostela, Palma de Mallorca, Badalona, Santander, Jerez de la Frontera, Las Palmas de Gran Canaria, El Palmar, Barcelona

2023-11-23

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsLumakras·Sotorasib·Pembrolizumab

Amgen

Phase 3

750

Málaga, Seville, Zaragoza, Palma de Mallorca, Las Palmas de Gran Canaria, Santander, Valladolid, Barcelona

2023-11-16

Recruiting

Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients

NCT06955702Breast Neoplasms, Alopecia, Madarosis, Eyebrow Diseases

University of Salamanca

Not applicable

120

Santander, Salamanca

2023-11-15

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Barcelona, Jaén, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Santander, Valencia, Zaragoza

2023-11-14

Active, closed

A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain

NCT06125795Chronic Lymphocytic Leukemia

AbbVie

Observational

146

Vitoria-Gasteiz, Manresa, Terrassa, Jerez de la Frontera, Laredo, Santander, Las Palmas de Gran Canaria, León

2023-11-06

Recruiting

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

NCT05762211Transplant Complication

DrugPooled allogeneic fecal microbiotherapy

MaaT Pharma

Phase 2

387

Barcelona, Granada, Madrid, Majadahonda, Murcia, Pamplona, Salamanca, Santander

2023-10-31

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Badalona, Sabadell, Bilbao, Santander, Vigo, A Coruña, Barcelona, Córdoba

2023-10-27

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Badalona, Barcelona, Santander, Santiago de Compostela, Málaga, Madrid, Majadahonda, Oviedo

2023-10-25

Recruiting

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037Lung Transplant Rejection

DrugsBelumosudil·Azithromycin

Sanofi

Phase 3

180

Santander, Barcelona, A Coruña, Majadahonda, Valencia

2023-10-10

Active, closed

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

NCT05888493Follicular Lymphoma (FL)

DrugTisagenlecleucel

Novartis Pharmaceuticals

Phase 3

109

Santiago Compostela, L'Hospitalet de Llobregat, Santander, El Palmar, Barcelona, Córdoba, Madrid, Salamanca

2023-10-02

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Badalona, L'Hospitalet de Llobregat, Barakaldo, Santander, Majadahonda, Badajoz, Barcelona, L'Hospitaler de Llobregat

2023-09-22

Active, closed

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Sorafenib·Lenvatinib

AbbVie

Phase 2

130

Santander, Córdoba, Majadahonda, Pamplona, Barcelona, Madrid, Seville, Zaragoza

2023-09-21

Active, closed

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

NCT05849610High-Risk de Novo Multiple Myeloma

DrugsTalquetamab·Teclistamab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Murcia, Pamplona, Salamanca, Santander, Santiago de Compostela

2023-09-21

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Santiago de Compostela, Vitoria-Gasteiz, Palma, Palma Mallorca, Badalona, Terrassa, Santander, León

2023-09-18

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Santander, Santiago de Compostela, Madrid, Majadahonda, Barcelona, Girona, Oviedo, Pamplona

2023-09-14

Active, closed

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis

DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

270

Barcelona, Santander, Córdoba, Málaga

2023-09-13

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Mérida, Santander, San Cristóbal de La Laguna, A Coruña, Santiago de Compostela, Seville

2023-09-11

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Málaga, Santander, Seville

2023-09-07

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

DrugOlverembatinib

Ascentage Pharma Group Inc.

Phase 3

350

Badalona, Barcelona, Cáceres, Madrid, Santander, Seville, Valencia

2023-08-31

Active, closed

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

NCT06059001Metastatic Pancreatic Cancer

DrugsOMO-103·Nab-paclitaxel·Gemcitabine

Peptomyc S.L.

Phase 1

Barcelona, L'Hospitalet de Llobregat, Santander, Madrid, Málaga, Zaragoza

2023-08-31

Active, closed

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769Chronic Obstructive Pulmonary Disease

DrugAstegolimab

Hoffmann-La Roche

Phase 3

2,000

Mérida, Palma de Mallorca, Santander, Santiago de Compostela, Torrejón de Ardoz, Benalmádena Costa, Alzira, Barcelona

2023-06-28

Recruiting

A Retrospective Study to Characterize Participants With Propionic Acidemia

NCT05769621Propionic Acidemia

ModernaTX, Inc.

Observational

Esplugues de Llobregat, Santander, Barakaldo, Madrid, Seville, Valencia

2023-06-16

Recruiting

eUltra 10k - Biofreedom Ultra

NCT05505929Post Market Clinical Follow up (PMCF)

Biosensors Europe SA

Observational

10,000

Santander

2023-06-15

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

NCT05841537Crohn's Disease

AbbVie

Observational

1,019

Santiago de Compostela, L'Hospitalet de Llobregat, Santander, Majadahonda, El Palmar, Vigo, Huelva, Madrid

2023-06-09

Recruiting

Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer

NCT06889883Colorectal Carcinoma, Advanced Adenomas (AA)

ADVANCED MARKER DISCOVERY S.L.

Observational

510

Zaragoza, Bilbao, Donostia / San Sebastian, Santander, Salamanca, Barcelona, Madrid, Oviedo

2023-06-06

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT05908409Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified

DrugIDP-121

IDP Discovery Pharma S.L.

Phase 1/2

Santander, Salamanca, Barcelona, Madrid, Murcia, Seville, Valencia, Zaragoza

2023-06-05

Active, closed

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

NCT05810870Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

DrugEribulin

MedSIR

Phase 2

Granada, Seville, Donostia / San Sebastian, Santander, A Coruña, Torrejón de Ardoz, Vigo, Barcelona

2023-05-24

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

A Coruña, Barcelona, Córdoba, Elche, Madrid, Pamplona, Santander

2023-05-03

Recruiting

OROPHARYNGEAL MYOFUNCTIONAL THERAPY IN OBSTRUCTIVE SLEEP APNEA

NCT06681974Obstructive Sleep Apnea

Instituto de Investigación Marqués de Valdecilla

Phase 3

Santander

2023-05-01

Active, closed

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

DrugABBV-319

AbbVie

Phase 1

Santander, Madrid

2023-04-26

Active, closed

Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

NCT06459648Migraine

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Observational

350

Zaragoza, Donostia / San Sebastian, Santander, Valladolid, Barcelona, Madrid, Valencia

2023-04-26

Active, closed

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

NCT07304843Primary Biliary Cholangitis (PBC)

Umecrine Cognition AB

Phase 1/2

202

Barcelona, Madrid, Málaga, Pontevedra, Santander, Seville, Valencia

2023-04-14

By invitation

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

NCT05669989Plasma Cell Myeloma

DrugsIsatuximab·Carfilzomib·Cemiplimab·Pomalidomide

Sanofi

Phase 2

Seville, Santander, Badalona, Madrid, Pamplona, Salamanca

2023-04-05

Active, closed

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

NCT05785611Axial Spondyloarthritis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

495

Alicante, Barcelona, Bilbao, Córdoba, Madrid, Santander, Santiago de Compostela, Seville

2023-04-05

Active, closed

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

NCT05723562Neoplasms, Rectal

DrugDostarlimab

GlaxoSmithKline

Phase 2

154

Barcelona, Granada, Madrid, Santander, Valencia

2023-04-03

Active, closed

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906Biochemically Recurrent Prostate Cancer

DrugDarolutamide

Bayer

Phase 3

985

Santiago de Compostela, Santander, Barcelona, Cadiz, Madrid, Málaga, Murcia, Seville

2023-04-03

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma

DrugsLifileucel·Pembrolizumab

Iovance Biotherapeutics, Inc.

Phase 3

670

Santander, Málaga, Barcelona, Madrid, Pamplona, Seville, Valencia

2023-03-30

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632Multiple Myeloma

DrugEtentamig

AbbVie

Phase 1

210

Santander, Majadahonda, Salamanca

2023-03-21

Active, closed

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease

Merck Sharp & Dohme LLC

Phase 2

129

Santander, Barcelona, Seville

2023-03-16

Active, closed

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT05649748Pulmonary Arterial Hypertension

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 2/3

Santander, Seville

2023-03-07

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

160

Barcelona, Málaga, Santander, Seville

2023-03-06

Active, closed

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

NCT05639114Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

436

Santiago Compostela, Elche, Badalona, Santander, Barcelona, San Sebastian Reyes, Pamplona, Vigo

2023-03-02

Active, closed

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899High-risk Large B-cell Lymphoma (LBCL)

DrugsAxi-cel·Axicabtagene Ciloleucel·Vincristine·Doxorubicin

Kite, A Gilead Company

Phase 3

300

Barcelona, Madrid, Salamanca, Santander, Seville, Valencia

2023-02-10

Active, closed

Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant

NCT05186857Graft-versus-host Disease

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Observational

Santander, Córdoba, Granada, Madrid, Málaga, Salamanca, Seville, Valencia

2023-01-23

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05702229Gastric Cancer

DrugsSonesitatug Vedotin·Volrustomig·Xelox·Rilvegostomig

AstraZeneca

Phase 2

163

Barcelona, Elche(Alicante), L'Hospitalet de Llobregat, Madrid, Santander

2023-01-16

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

Badalona, Santander, Barcelona, Oviedo, Granada, Lugo, Madrid, Seville

2023-01-16

Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

DrugsVepugratinib·Digoxin·Enfortumab Vedotin·Rosuvastatin

Eli Lilly and Company

Phase 1

677

Barcelona, Madrid, Santander

2023-01-12

Active, closed

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

513

Mérida, Barcelona, Bilbao, Santander, Cordoba, Seville, Valencia, Valladolid

2023-01-12

Active, closed

Phase 2b Study of GSK4532990 in Adults With NASH

NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease

DrugGSK4532990

GlaxoSmithKline

Phase 2

284

Barcelona, Madrid, Málaga, Sabadell Barcelona, Santander, Seville, Vigo

2023-01-02

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

NCT05306041HER2-positive Breast Cancer

DrugsPhesgo·Inavolisib

GBG Forschungs GmbH

Phase 2

170

Barcelona, Granada, Lleida, Madrid, Murcia, Palma de Mallorca, Santander, Seville

2023-01-02

Active, closed

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266NSCLC

DrugsDato-DXd·Durvalumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 3

1,350

Las Palmas de Gran Canaria, Lugo, Madrid, Santander, Seville, Valencia, Zaragoza

2022-12-29

Active, closed

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

NCT05527340Multiple Myeloma

DrugsIberdomide·Daratumumab·Dexamethasone

PETHEMA Foundation

Phase 2

140

Madrid, Palma de Mallorca, Pamplona, Salamanca, San Cristóbal de La Laguna, Santander, Seville, Valencia

2022-12-15

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Barcelona, Madrid, Majadahonda, Málaga, Ourense, Palma de Mallorca, Pamplona, Santander

2022-12-13

Active, closed

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

NCT05608044Metastatic Colorectal Cancer

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

234

Barcelona, Madrid, Pamplona, Santander

2022-11-30

Active, closed

Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

NCT05659914Metastatic Pancreatic Cancer

DrugsOlaparib·Durvalumab

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Phase 2

A Coruña, Barcelona, Santander

2022-11-28

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Santiago de Compostela, Badalona, L'Hospitalet Del Llobregat, Terrassa, Santander, Barcelona, Girona, Madrid

2022-11-10

Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

NCT05372354Multiple Myeloma

DrugsBMS-986158·Tazemetostat·Mezigdomide·Trametinib

Bristol-Myers Squibb

Phase 1/2

260

Barcelona, Madrid, Santander

2022-10-18

Active, closed

Optilume Registry for Treatment of Stricture of the Anterior Urethra

NCT05479422Anterior Urethral Stricture, Male

European Association of Urology Research Foundation

Observational

150

Santander, Madrid, Pamplona

2022-10-13

Active, closed

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Badalona, L'Hospitalet de Llobregat, Santander, Córdoba, Pamplona, Barcelona, Cáceres, Madrid

2022-09-20

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Barcelona, Madrid, Pamplona, Pontevedra, Sabadell, Santander, Torrejón de Ardoz, Vigo

2022-09-19

Active, closed

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327Systemic Lupus Erythematosus

DrugEnpatoran

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2

379

Castelló, Málaga, Santander, Valladolid

2022-09-16

Active, closed

XIENCE Skypoint Large Vessel Post Approval Study

NCT05423379Coronary Artery Disease

Abbott Medical Devices

Observational

102

Madrid, Santander, Seville

2022-09-14

Active, closed

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

NCT05570058IPF, Fibrosis

Redx Pharma Ltd

Phase 2

Barcelona, Madrid, Oviedo, Santander, Santiago de Compostela

2022-09-08

Recruiting

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

NCT05398679Endocarditis Infective

DrugsCefaclor·Dicloxacillin·Clindamycin·Ciprofloxacin

Fundacion Clinic per a la Recerca Biomédica

Phase 4

360

Alicante, Seville, Palma de Mallorca, Barcelona, Sabadell, Terrassa, Barakaldo, Santander

2022-08-17

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

Santiago de Compostela, Badalona, Santander, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Salamanca

2022-08-17

Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

DrugsAbraxane·Nab-paclitaxel·Gemcitabine

Panbela Therapeutics, Inc.

Phase 2/3

600

Badalona, Santander, Jaén, Barcelona, Madrid, El Palmar, Pamplona, Barakaldo

2022-08-08

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

Santander, Vigo, Barcelona, Córdoba, Madrid, Valencia

2022-08-04

Recruiting

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

NCT05379595Advanced or Metastatic Colorectal Cancer

DrugsAmivantamab·Fluorouracil·Leucovorin·Irinotecan

Janssen Research & Development, LLC

Phase 1/2

225

Barcelona, Madrid, Santander, Valencia

2022-07-29

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

DrugsPirtobrutinib·Ibrutinib

Loxo Oncology, Inc.

Phase 3

737

Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Marbella, Pamplona, Santander, Seville

2022-07-22

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Madrid, Pamplona, Pontevedra, Sabadell, Santander, Torrejón de Ardoz

2022-07-22

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santander, Seville

2022-07-08

Active, closed

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634Myositis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2

Barcelona, Madrid, Santander

2022-07-05

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

NCT05203172Solid Tumors

DrugsVemurafenib·Binimetinib·Encorafenib·Zirabev

Pfizer

Phase 4

210

A Coruña, Badalona, Barcelona, Santander, Lleida, Majadahonda, Madrid, Málaga

2022-07-05

Active, closed

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

NCT05405166Plasma Cell Myeloma Recurrent

DrugsParacetamol / Acetaminophen·Montelukast·Diphenhydramine·Isatuximab

Sanofi

Phase 3

531

Murcia, Badalona, Santander, Pamplona, Madrid, Salamanca

2022-06-23

Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease

AC Immune SA

Phase 1/2

304

Barcelona, Granada, Madrid, Santander, Valencia

2022-06-21

By invitation

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

NCT05352919Systemic Lupus Erythematosus (SLE)

DrugLitifilimab

Biogen

Phase 3

864

Castellon, Santander, Seville, Barcelona

2022-06-10

Active, closed

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

NCT05028348Multiple Myeloma

DrugsElotuzumab·Selinexor·Pomalidomide·Dexamethasone

European Myeloma Network B.V.

Phase 3

117

Barcelona, Gijón, Girona, Madrid, Murcia, Pamplona, Salamanca, Santander

2022-04-19

Recruiting

Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy

NCT04056533CMV

Instituto de Investigación Marqués de Valdecilla

Phase 2

Santander

2022-03-26

Active, closed

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

MaaT Pharma

Phase 3

Barcelona, El Palmar, Granada, Madrid, Murcia, Pamplona, Salamanca, Santander

2022-03-25

Active, closed

COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease

Diagram B.V.

Not applicable

1,223

Barcelona, Madrid, Santander, Valencia

2022-03-16

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

A Coruña, Barakaldo, Barcelona, Bilbao, Córdoba, Ferrol, Madrid, Santander

2022-03-15

Recruiting

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes

DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax

Sumitomo Pharma America, Inc.

Phase 1/2

606

Albacete, Barcelona, Cáceres, Las Palmas, Madrid, Oviedo, Salamanca, Santander

2022-02-28

Active, closed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

DrugsEvorpacept·Ramucirumab·Herceptin·Taxol

ALX Oncology Inc.

Phase 2/3

127

Alicante, Badalona, Barcelona, Córdoba, Lugo, Madrid, Santander, Zaragoza

2022-01-15

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Seville, Valencia

2021-12-14

Active, closed

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT04954859Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

360

HebrOn, León, Madrid, Santander, Valencia, Vigo

2021-12-14

Active, closed

Registry for Patients Undergoing Penile Prosthesis Implantation for Male Erectile Dysfunction

NCT03849586Erectile Dysfunction

European Association of Urology Research Foundation

Observational

1,076

Barcelona, Boadilla del Monte, Madrid, Majadahonda, Móstoles, Palma de Mallorca, Santander

2021-11-19

Active, closed

Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II

NCT04893291Coronary Artery Disease, Coronary Artery Stenosis

Fondazione Ricerca e Innovazione Cardiovascolare ETS

Not applicable

1,820

Ciudad Real, Lugo, Madrid, Santander, Valencia, Vigo, Vitoria-Gasteiz

2021-11-16

Recruiting

Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis

NCT04924868Acute Pancreatitis Due to Gallstones

DrugUrsodeoxycholic Acid

Hospital General Universitario de Alicante

Phase 3

332

Santiago de Compostela, Alicante, Elche, Barcelona, L'Hospitalet de Llobregat, Sabadell, Santander, Granada

2021-11-10

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Córdoba, Seville, Santander, Salamanca, Badalona, Barcelona, L'Hospitalet de Llobregat, Valencia

2021-11-02

Active, closed

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696Systemic Lupus Erythematosus

Beeline Medicines Corporation

Phase 2

248

Santander, A Coruña, Barcelona, Madrid, Seville

2021-10-11

Active, closed

Study of Lacutamab in Peripheral T-cell Lymphoma

NCT04984837Peripheral T Cell Lymphoma, Relapse/Recurrence

DrugsOxaliplatine·Gemcitabine

The Lymphoma Academic Research Organisation

Phase 2

Barcelona, Madrid, Santander, Valencia

2021-10-05

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Santiago de Compostela, L'Hospitalet Del Llobregat, Terrassa, Santander, Pamplona, Toledo, Barcelona, Girona

2021-10-04

Active, closed

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04909801Rheumatoid Arthritis

DrugsAbatacept·Humira·Adalimumab·Methotrexate

Bristol-Myers Squibb

Phase 3

338

A Coruña, Madrid, Santander

2021-09-15

Active, closed

A Multi-Center Post-Market Data Collection Protocol to Evaluate the Performance of Orthofix Spine Devices

NCT05082090Spinal Disorders/Injuries

Orthofix Inc.

Observational

2,000

Barcelona, Palma de Mallorca, Santander

2021-09-15

Recruiting

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT04704323Lymphocytic Leukemia, Chronic, SLL

Catapult Therapeutics

Phase 1

Madrid, Santander

2021-09-10

Active, closed

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

NCT04827953Pancreatic Ductal Adenocarcinoma

DrugsNLM-001·Zalifrelimab·Nab-paclitaxel·Gemcitabine

Nelum Corp

Phase 1/2

Santiago de Compostela, Málaga, Zaragoza, Donostia / San Sebastian, Barcelona, Santander

2021-09-01

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Santander, Seville

2021-08-19

Active, closed

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

NCT04908189Psoriatic Arthritis

DrugsApremilast·Deucravacitinib

Bristol-Myers Squibb

Phase 3

729

Barcelona, Madrid, Santander, Valencia

2021-07-15

Recruiting

Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

NCT04927156Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases

Balt Extrusion

Observational

10,000

Madrid, Oviedo, Santander, Zaragoza

2021-07-12

Recruiting

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

European Foundation for Study of Chronic Liver Failure

Observational

3,000

Barcelona, Madrid, Santander, Seville, Valencia

2021-07-08

Active, closed

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722Colorectal Cancer

DrugsPembrolizumab/Vibostolimab·MK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab

Merck Sharp & Dohme LLC

Phase 2

302

Santander, Barcelona, Madrid, Málaga, Pamplona, Oviedo, Valencia

2021-06-25

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Barcelona, Bilbao (Vizcaya), Granada, Madrid, Salamanca, Santander, Santiago de Compostela-Coruña, Seville

2021-06-22

By invitation

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

NCT04451044Coronary Artery Disease, Ischemic Heart Disease

Philips Clinical & Medical Affairs Global

Not applicable

3,212

Córdoba, León, Madrid, Santander

2021-06-17

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

548

Santander, Valladolid, Barcelona, Granada, Seville, Valencia

2021-05-25

Active, closed

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

NCT04810078Clear Cell Renal Cell Carcinoma

DrugsNivolumab and rHuPH20·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

681

Barcelona, Madrid, Sabadell, Santander, Seville

2021-05-21

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Palma de Mallorca, Santander, Barcelona, Majadahonda, Madrid, Toledo

2021-05-12

Active, closed

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344Muscle-invasive Bladder Cancer

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Phase 3

761

Sabadell, Santander, Córdoba, Donostia / San Sebastian, Barcelona, Madrid, Seville, Valencia

2021-05-03

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer

DrugPhase 2

enGene, Inc.

Phase 1/2

350

Barbera Del Valles, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Santander

2021-04-22

Recruiting

A Population-based Cohort in Northern Spain

NCT05852678Chronic Disease

Instituto de Investigación Marqués de Valdecilla

Observational

22,000

Santander

2021-04-20

Active, closed

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706Carcinoma, Renal Cell

DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda

Merck Sharp & Dohme LLC

Phase 3

1,688

Santander, Barcelona, Girona, Madrid, Málaga

2021-04-14

Active, closed

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

NCT04802356Multiple Myeloma

DrugsBelantamab mafodotin·Bortezomib·Lenalidomide·Dexamethasone

PETHEMA Foundation

Phase 2

Palma de Mallorca, Santander, Salamanca, Santiago de Compostela, Madrid, Gijón, Valencia, Las Palmas de Gran Canaria

2021-04-07

Active, closed

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181Non-alcoholic Steatohepatitis

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,205

Pontevedra, Barcelona, Majadahonda, Santander, Seville, Valencia, Valladolid

2021-04-01

Active, closed

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

NCT04817007Myelofibrosis

DrugsBMS-986158·Fedratinib·Ruxolitinib

Bristol-Myers Squibb

Phase 1/2

216

Badalona, Santander, Madrid, Salamanca, Valencia

2021-03-22

Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576Chronic Graft-versus-host-disease

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

296

Seville, Barcelona, Donostia / San Sebastian, Granada, Madrid, Majadahonda, Salamanca, Santander

2021-03-04

Active, closed

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318Chronic Lymphoid Leukemia

DrugsVenclyxto·Ibrutinib·Obinutuzumab·Venetoclax

German CLL Study Group

Phase 3

897

Badalona, Barcelona, Madrid, Málaga, Oviedo, Salamanca, Santander, Seville

2021-03-01

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552Hematological Malignancies

DrugTalquetamab

Janssen Research & Development, LLC

Phase 2

510

Badalona, Barcelona, Madrid, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2021-02-01

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Barcelona, Jaén, Lleida, Madrid, Málaga, Pamplona, Santander, Seville

2021-01-28

Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer

DrugsIrinotecan·Gemcitabine

Artios Pharma Ltd

Phase 1/2

542

Elche, Sabadell, Santander, Barcelona, Lleida, Madrid, Pozuelo de Alarcón, El Palmar

2021-01-27

Active, closed

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

NCT04657991Melanoma

DrugsBinimetinib·Encorafenib·Keytruda·Pembrolizumab

Pfizer

Phase 3

257

Badalona, Santander, Majadahonda, El Palmar, A Coruña, Barcelona, Córdoba, Jaén

2021-01-15

Recruiting

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242Pediatric Migraine

Pfizer

Phase 3

2,100

Santander, Barcelona, Madrid, Seville, Valladolid

2021-01-15

Active, closed

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

181

Seville, Santander, Salamanca, Badalona, Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat, Pamplona

2021-01-04

Recruiting

Secukinumab Open Label Roll-over Extension Protocol

NCT04638647Autoimmunity, Inflammation

DrugSecukinumab

Novartis Pharmaceuticals

Phase 4

1,000

Santiago Compostela, Málaga, L'Hospitalet de Llobregat, Bilbao, Santander, Vigo, A Coruña, Madrid

2020-12-22

Active, closed

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04586426Multiple Myeloma

DrugsTalquetamab·Teclistamab

Janssen Research & Development, LLC

Phase 1/2

228

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca, Santander

2020-12-15

Active, closed

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin

Janssen Research & Development, LLC

Phase 3

518

A Coruña, Badalona, Barcelona, Granada, Jerez de la Frontera, Madrid, Sabadell, Santander

2020-12-07

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Barcelona, Madrid, Málaga, Ourense, Santander, Seville, Valencia

2020-11-17

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Barcelona, Córdoba, Madrid, Pamplona, Santander, Zaragoza

2020-10-19

Active, closed

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

NCT04293393Early Breast Cancer

DrugsLeuprolide·Goserelin·Pegylated liposomal doxorubicin·Abemaciclib

Spanish Breast Cancer Research Group

Phase 2

200

Santiago de Compostela, L'Hospitalet de Llobregat, Santander, Castellon, San Sebastián, Vigo, A Coruña, Alicante

2020-10-02

Active, closed

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

NCT04483739Multiple Myeloma

European Myeloma Network B.V.

Phase 3

302

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander

2020-09-25

Active, closed

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

NCT04526665Primary Biliary Cirrhosis

DrugElafibranor

Ipsen

Phase 3

161

Barcelona, Madrid, Pontevedra, San Sebastián, Santander, Seville

2020-09-24

Active, closed

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098Hematological Malignancies

DrugTeclistamab

Janssen Research & Development, LLC

Phase 2

194

Badalona, Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2020-09-17

Active, closed

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

DrugsLoncastuximab Tesirine·Rituximab·Oxaliplatin·Gemcitabine

ADC Therapeutics S.A.

Phase 3

440

Barcelona, Cáceres, Madrid, Santander, Seville, Valencia

2020-09-16

Recruiting

AutoInflammatory Disease Alliance Registry (AIDA)

NCT05200715Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome

University of Siena

Observational

3,500

Barakaldo, Barcelona, Madrid, Santander, Valencia

2020-08-06

Active, closed

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

NCT04191304Hypereosinophilic Syndrome

DrugBenralizumab

AstraZeneca

Phase 3

134

Santander

2020-07-20

Active, closed

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms

DrugsZelenectide pevedotin·Keytruda·Pembrolizumab

BicycleTx Limited

Phase 1/2

329

Barcelona, Madrid, Pozuelo de Alarcón, Santander

2020-07-17

Active, closed

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease

DrugLecanemab

Eisai Inc.

Phase 3

1,400

Barcelona, Donostia / San Sebastian, Madrid, Santander

2020-07-14

Active, closed

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853Hormone-Sensitive Prostate Cancer

DrugsZytiga·Capivasertib·Abiraterone acetate

AstraZeneca

Phase 3

1,012

Badalona (Barcelona), Barcelona, Las Palmas de Gran Canaria, Madrid, Oviedo, Santander, Seville

2020-07-13

Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma

DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 1

1,006

Madrid, Elche, Santander, Barcelona, Jerez de la Frontera, Málaga

2020-06-08

Active, closed

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596Gastric Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Fluorouracil

AstraZeneca

Phase 2

452

Barcelona, Madrid, Santander, Seville

2020-06-03

Active, closed

Lifestyles and Breast Cancer

NCT04174391Malignant Tumor of Breast

University of Navarra

Not applicable

766

Santander, Granada, Jaén, Pamplona

2020-05-29

Active, closed

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856Urothelial Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Astellas Pharma Global Development, Inc.

Phase 3

886

Barcelona, Córdoba, Lugo, Madrid, Manresa, Pamplona, Sabadell, Santander

2020-03-30

Active, closed

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

NCT04277637Mature B-Cell Malignancies

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 1

437

Barcelona, Madrid, Salamanca, Santander

2020-03-24

Recruiting

Erythrocyte Transport of Lactate During Exercise (TELE Project)

NCT06104150Energy Metabolism

Technical University of Madrid

Not applicable

Santander, Madrid

2020-02-03

Active, closed

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

NCT04091126Multiple Myeloma

DrugsBelantamab mafodotin·Bortezomib·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 1

118

Badalona, Barcelona, Madrid, Málaga, PamplonaNavarra, Pozuelo de AlarcOn Madr, Santander

2019-12-18

Active, closed

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251Melanoma

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

790

Barcelona, A Coruña, Badalona, Madrid, Málaga, Santander, Valencia

2019-10-28

Active, closed

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

NCT03768570Bladder Cancer

DrugDurvalumab

Canadian Cancer Trials Group

Phase 2

Barcelona, Madrid, Santander, Valencia

2019-10-25

Active, closed

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

NCT04041310Solid Tumor, Adult

DrugsKeytruda·Pembrolizumab

Nouscom SRL

Phase 1/2

115

A Coruña, Barcelona, Córdoba, Granada, Madrid, Pamplona, Salamanca, Santander

2019-10-21

Active, closed

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414Multiple Myeloma

DrugsElotuzumab·Mezigdomide·Isatuximab·Carfilzomib

Celgene

Phase 1/2

424

Badalona, Madrid, Málaga, Pamplona, Salamanca, Santander, Valencia

2019-09-30

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Badalona, Barcelona, Girona, Madrid, Santander, Seville

2019-09-26

Recruiting

A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

NCT03911128Leukemia, Acute Lymphoblastic

Mats Heyman

Observational

500

Alicante, Barakaldo, Barcelona, Fuencarral-El Pardo, Madrid, Murcia, Palma de Mallorca, Santander

2019-08-29

Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

NCT04064359Solid Tumor

Oxford BioTherapeutics Ltd

Phase 1

200

Barcelona, Madrid, Santander

2019-07-25

Active, closed

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

NCT03873402Renal Cell Carcinoma

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

437

Barcelona, Córdoba, Madrid, Pamplona, Sabadell, Santander, Santiago Compostela, Seville

2019-06-21

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429NASH - Nonalcoholic Steatohepatitis

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

1,759

Majadahonda, Almería, Barcelona, Madrid, Pontevedra, Santander, Seville, Valencia

2019-03-28

Active, closed

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

NCT03869892Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Capecitabine

Institut de Recherches Internationales Servier

Phase 3

856

Alicante, Badalona, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Santander, Seville

2019-03-21

Active, closed

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Chronic Lymphocytic Leukemia

DrugsVenclyxto·Acalabrutinib·Venclexta·Obinutuzumab

Acerta Pharma BV

Phase 3

984

Badalona, Barcelona, Madrid, Majadahonda, Salamanca, Santander, Valencia

2019-02-25

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

NCT03748641Castration-Resistant Prostatic Cancer

DrugsAbiraterone acetate·Niraparib·Prednisone

Janssen Research & Development, LLC

Phase 3

765

A Coruña, Barcelona, Jerez de la Frontera, Madrid, Málaga, Pozuelo de Alarcón, Sabadell, Santander

2019-01-25

Active, closed

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677Muscle Invasive Bladder Cancer

DrugsDurvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,063

Badalona, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville

2018-11-16

Active, closed

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,246

Barcelona, Lugo, Madrid, Málaga, Santander, Seville

2018-09-27

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Palma, Palma de Mallorca, L'Hospitalet de Llobregat, San Sebastian- Donostia, Santander, Badalona, Barcelona, Santiago de Compostela

2018-08-21

Active, closed

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

NCT03605771Melanoma Stage Iv, Melanoma Stage Iii, Advanced Cancer

Grupo Español Multidisciplinar de Melanoma

Observational

400

Alcoy, Granada, Málaga, Barcelona, Sabadell, Vitoria-Gasteiz, Santander, Burgos

2018-08-07

Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796Neoplasms

Celgene

Phase 2/3

1,541

Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Málaga, Pamplona, Salamanca, Santander

2018-07-19

Recruiting

Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

NCT03855592Thromboembolism, Cancer

Fundación Sociedad Española de Oncologia Médica

Observational

700

Alcoy, Elche, Palma, L'Hospitalet de Llobregat, Sabadell, Sant Joan Despí, Santander, Jerez de la Frontera

2018-07-04

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

NCT03755791Hepatocellular Carcinoma

DrugsSorafenib·Cabozantinib·Tecentriq·Atezolizumab

Exelixis

Phase 3

837

Santander, Majadahonda, Pamplona, Barcelona, Madrid, Valencia, Zaragoza

2018-06-10

Active, closed

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

NCT03473743Urothelial Carcinoma

DrugsErdafitinib·Cetrelimab·Cisplatin·Carboplatin

Janssen Research & Development, LLC

Phase 1/2

125

Barcelona, Madrid, Málaga, Ourense, Pontevedra, Pozuelo de Alarcón, Sabadell, Santander

2018-04-05

Active, closed

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

747

Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, A Coruña, Barcelona, Girona, Huelva

2018-03-21

Recruiting

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT03394365Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant

DrugTabelecleucel

Pierre Fabre Medicament

Phase 3

115

Badalona, Barcelona, Santander, Madrid, Seville, Valencia

2017-12-29

Active, closed

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

NCT03301506Primary Biliary Cirrhosis

DrugSeladelpar

Gilead Sciences

Phase 3

340

Badalona, Barcelona, Horcajo de la Sierra, Madrid, Málaga, Santander

2017-12-12

Active, closed

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451Hepatocellular Carcinoma

DrugsSorafenib·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

1,324

Barcelona, Madrid, Oviedo, Pamplona Madrid, Santander

2017-10-11

Active, closed

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872Small Cell Lung Carcinoma Extensive Disease

DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin

AstraZeneca

Phase 3

987

A Coruña, Badajoz, Badalona, Barcelona, Madrid, Santander, Valencia, Zaragoza

2017-03-27

Active, closed

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

NCT03036098Urothelial Cancer

DrugsYervoy·Ipilimumab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

1,314

A Coruña, Barcelona, Madrid, Santander, Seville, Valencia

2017-03-24

Active, closed

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696Non-Hodgkin's Lymphoma

DrugsGlofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

940

Badalona, L'Hospitalet de Llobregat, Santander, Barcelona, Madrid

2017-02-21

Active, closed

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318Chronic Lymphocytic Leukemia

DrugsIdelalisib·Acalabrutinib·Bendamustine·Rituximab

Acerta Pharma BV

Phase 3

310

Badalona, Madrid, Majadahonda, Salamanca, Santander, Valencia

2017-02-02

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068Ulcerative Colitis (UC)

DrugUpadacitinib

AbbVie

Phase 3

950

A Coruña, Santiago de Compostela, Santander, Las Palmas de Gran Canaria, Barcelona, Córdoba, Madrid, Salamanca

2017-01-31

Active, closed

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

NCT02954094Hepatocellular Cancer

Target PharmaSolutions, Inc.

Observational

10,000

Madrid, Pamplona, Santander, Seville, Valencia

2016-12

Active, closed

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861Renal Cell Carcinoma

DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab

Eisai Inc.

Phase 3

1,069

Santander, Barcelona, Cáceres, Córdoba, Madrid, Oviedo, Seville, Valencia

2016-10-13

Active, closed

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776Non-Small-Cell Lung Cancer

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 1

751

A Coruña, Barcelona, Madrid, Málaga, Santander, Seville

2016-05-24

Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707Community-acquired Pneumonia, Influenza, COVID-19

DrugsConvalescent plasma·Repagermanium·Ivermectin·Telmisartan

UMC Utrecht

Phase 3

20,000

Barcelona, Cadiz, Córdoba, Madrid, Málaga, Ourense, Santander, Tortosa

2016-04-11

Active, closed

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284Neoplasms

DrugDostarlimab

Tesaro, Inc.

Phase 1

729

Santiago de Compostela, Barcelona, Girona, Madrid, Málaga, Murcia, Pamplona, Santander

2016-03-07

Active, closed

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159Rheumatoid Arthritis

DrugsHumira·Adalimumab·Upadacitinib

AbbVie

Phase 3

1,629

Santander, A Coruña, Córdoba, Santiago de Compostela

2015-12-01

Active, closed

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

NCT02477696Chronic Lymphocytic Leukemia

DrugsIbrutinib·Acalabrutinib

Acerta Pharma BV

Phase 3

533

Barcelona, Madrid, Majadahonda, Murcia, Santander

2015-07-28

Active, closed

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681Chronic Lymphocytic Leukemia

DrugsChlorambucil·Acalabrutinib·Obinutuzumab

Acerta Pharma BV

Phase 3

535

Barcelona, Madrid, Majadahonda, Santander

2015-06-26

Recruiting

The European NAFLD Registry

NCT04442334NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver

Newcastle University

Observational

10,000

Barcelona, Donostia / San Sebastian, Majadahonda, Santander, Seville, Valladolid

2015-05-01

Active, closed

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

NCT02365597Urothelial Cancer

DrugsErdafitinib·Midazolam·Metformin

Janssen Research & Development, LLC

Phase 2

239

Badalona, Barcelona, Madrid, Málaga, Pamplona, Sabadell, Santander, Santiago de Compostela

2015-04-22

Active, closed

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

NCT02320435Solid Tumors

DrugsPerjeta·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

154

L'Hospitalet de Llobregat, Santander, San Cristóbal de La Laguna, Bilbao, Barcelona, Valencia

2015-02-02

Recruiting

RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

NCT01719055Pain

Boston Scientific Corporation

Observational

4,800

Ciudad Real, Madrid, Pamplona, San Sebastián, Santander, Toledo, Valencia

2012-11-19

Recruiting

The EUROSCA Natural History Study

NCT02440763Spinocerebellar Ataxia

Ataxia Study Group

Observational

400

Santander

2005-07

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/santander

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 405 of those studies with a site in Santander.

How many clinical trials are recruiting in Santander?

205 of the 405 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 12 have not yet opened recruitment, 184 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Santander), 405 studies
Phase	Studies	Recruiting	Share
Phase 3	187	94	46.2%
Phase 2	100	37	24.7%
Observational	38	26	9.4%
Phase 1/2	25	13	6.2%
Phase 1	19	10	4.7%
Not applicable	15	9	3.7%
Phase 2/3	12	8	3%
Phase 4	9	8	2.2%

Most active sponsors

Lead sponsors with the most studies (Santander)
Lead sponsor	Studies	Recruiting
AstraZeneca	40	23
Janssen Research & Development, LLC	24	6
AbbVie	16	6
Bristol-Myers Squibb	16	4
Merck Sharp & Dohme LLC	15	6
GlaxoSmithKline	14	6
Novartis Pharmaceuticals	12	3
Hoffmann-La Roche	11	3
Sanofi	9	3
Instituto de Investigación Marqués de Valdecilla	8	7

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.